Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
REALITY trial supports restrictive transfusion in anemic MI
Key clinical point: A restrictive transfusion strategy is best in acute MI patients with anemia.
Major finding: The 30-day major adverse cardiovascular events rate was 11% in patients randomized to a restrictive transfusion strategy and 14% with a liberal transfusion strategy.
Study details: REALITY was a prospective randomized trial including 668 patients with acute MI and anemia.
Disclosures: The study was funded by the French Ministry of Health and the Spanish Ministry of Economy and Competitiveness with no commercial support.
Citation:
Steg PG. ESC 2020.